We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-16.23%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
-$532M
Cap. Flow
-$18.1M
Cap. Flow %
-1.15%
Top 10 Hldgs %
64.59%
Holding
44
New
6
Increased
6
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$35M
2
CGEM icon
Cullinan Oncology
CGEM
+$29.4M
3
ZURA icon
Zura Bio
ZURA
+$24.6M
4
SYRE icon
Spyre Therapeutics
SYRE
+$17.3M
5
PCSC
Perceptive Capital Solutions
PCSC
+$7.55M

Top Sells

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$34.5M
2
MRUS
Merus
MRUS
+$25.5M
3
CELC icon
Celcuity
CELC
+$21M
4
IMTX icon
Immatics
IMTX
+$18.4M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.1B
$334M 21.28%
8,493,321
– –
ELVN icon
2
Enliven Therapeutics
ELVN
$3.92B
$94.1M 5.99%
4,026,331
– –
FDMT icon
3
4D Molecular Therapeutics
FDMT
$532M
$92.4M 5.88%
4,400,000
– –
OCUL icon
4
Ocular Therapeutix
OCUL
$1.79B
$87.3M 5.56%
12,762,462
– –
DYN icon
5
Dyne Therapeutics
DYN
$4.7B
$76.7M 4.89%
2,173,913
– –
MRUS
6
DELISTED
Merus
MRUS
$74.7M 4.76%
1,263,214
-527,000
-29% -$25.5M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$73.6M 4.69%
6,249,731
– –
PHVS icon
8
Pharvaris
PHVS
$2.28B
$63.8M 4.07%
3,395,606
– –
SYRE icon
9
Spyre Therapeutics
SYRE
$8.54B
$63.1M 4.02%
2,685,448
+513,666
+24% +$17.3M
DNTH icon
10
Dianthus Therapeutics
DNTH
$5.84B
$54.2M 3.45%
2,094,373
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$2.09B
$50.5M 3.22%
3,882,671
– –
COGT icon
12
Cogent Biosciences
COGT
$6.65B
$47.9M 3.05%
5,684,167
+555,000
+11% +$4.21M
APLT
13
DELISTED
Applied Therapeutics
APLT
$44.6M 2.84%
9,542,871
+467,871
+5% +$2.21M
ERAS icon
14
Erasca
ERAS
$6.3B
$38.3M 2.44%
+16,216,216
New +$35M
ATXS
15
DELISTED
Astria Therapeutics
ATXS
$32.8M 2.09%
3,608,645
– –
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.13B
$32.7M 2.09%
1,818,182
– –
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.15B
$31.1M 1.98%
4,394,527
– –
PRAX icon
18
Praxis Precision Medicines
PRAX
$8.58B
$29.2M 1.86%
706,131
+5
+0% +$236
ENGN icon
19
enGene Therapeutics
ENGN
$120M
$26.6M 1.7%
2,825,983
+260,142
+10% +$3.34M
CGEM icon
20
Cullinan Oncology
CGEM
$1.01B
$24.1M 1.53%
+1,379,965
New +$29.4M
TERN
21
DELISTED
Terns Pharmaceuticals
TERN
$23.2M 1.48%
3,410,058
– –
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
$22.8M 1.45%
453,120
– –
ZURA icon
23
Zura Bio
ZURA
$516M
$21.1M 1.34%
+6,023,166
New +$24.6M
TSHA icon
24
Taysha Gene Therapies
TSHA
$1.68B
$20.2M 1.28%
9,000,000
– –
ABVX
25
Abivax
ABVX
$10.9B
$17.8M 1.13%
1,345,780
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2024 Portfolio in Review

As of Q2 2024, VR Adviser held 44 positions worth $1.57B, down 25% from $2.1B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

VR Adviser's Q2 2024 filing shows 6 new, 6 increased, 3 reduced and 9 closed positions. Its largest new stake was Erasca: 16,216,216 shares worth $38.3M. The largest sale was HilleVax, an estimated $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • VR Adviser's largest Q2 2024 buy was Erasca: 16,216,216 shares worth $38.3M.
  • VR Adviser added most to Spyre Therapeutics in Q2 2024, an estimated $17.3M increase.
  • VR Adviser's biggest Q2 2024 reduction was Merus, cutting an estimated $25.5M.
  • VR Adviser fully exited HilleVax in Q2 2024, selling an estimated $34.5M.
  • VR Adviser's ten largest holdings make up 65% of its $1.57B portfolio in Q2 2024.
  • VR Adviser opened 6 new positions and closed 9 in Q2 2024.
  • VR Adviser's portfolio value fell 25% quarter-over-quarter to $1.57B.

Based on VR Adviser's 13F filing for Q2 2024, filed 14 Aug 2024.